Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection

Glioblastoma Multiforme Clinical Trial

Official title: Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope

Status Completed

Clinical Trial Summary

1. Primary outcome measure:

a.Evaluation of the treatment impact on progression-free survival.

2. Secondary outcome measures:

1. Safety evaluation.

• Direct effects attributable cell obtaining and administration.

• Adverse events during treatment.

• Neurological deterioration quantified using the NIH Stroke Scale.

• Autoimmune phenomena.

2. Evaluation of impact on other efficiency clinical parameters.

• Overall survival.

• Quality of life measured with EORTC questionnaire.

3. Study of specific immune response and correlates with clinical outcome.

• Delayed hypersensitivity.

• Humoral response to autologous tumor cells/tumoral lysate.

• Cellular response (proliferation, cytokine production, specific cytotoxicity).

4. Cell line characterization and correlate the final product with clinical efficacy.

• Phenotypic studies.

Clinical Trial Description

A prospective, open-label, unicentric phase II trial, historical control and non-randomized.

The study will try to evaluate the efficiency and safety of the experimental treatment using a cell therapy product (tumor lysate-pulsed autologous dendritic cell vaccine) in patients with glioblastoma multiforme in whom a gross total resection is feasible. Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme

• NCT number: NCT01006044
• Study type: Interventional
• Source: Clinica Universidad de Navarra, Universidad de Navarra
• Status: Completed
• Phase: Phase 2
• Start date: October 2009
• Completion date: August 2014